Korean Circ J.  2019 Mar;49(3):264-266. 10.4070/kcj.2019.0007.

Benefit, Risk and Cost in Oral Anticoagulation for Stroke Prevention: Is It the Third Factor?

• Choi JI

• KMID: 2438537
• DOI: http://doi.org/10.4070/kcj.2019.0007

Abstract

No abstract available.

MeSH Terms

Stroke*

Reference

1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383:955–962.

2. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39:1330–1393.

3. Shankar PR. Essential medicines and health products information portal. J Pharmacol Pharmacother. 2014; 5:74–75.

4. Neumann PJ, Sanders GD. Cost-effectiveness analysis 2.0. N Engl J Med. 2017; 376:203–205.

5. Shah A, Shewale A, Hayes CJ, Martin BC. Cost-effectiveness of oral anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation patients. Stroke. 2016; 47:1555–1561.

6. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013; 44:1676–1681.

7. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012; 110:845–851.

8. Kim H, Kim H, Cho SK, Kim JB, Joung B, Kim C. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Korean Circ J. 2019; 49:252–263.

9. Desteghe L, Vijgen J, Koopman P, et al. Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation. Eur Heart J. 2018; 39:1394–1403.

10. Sabbag A, Yao X, Siontis KC, Noseworthy PA. Anticoagulation for stroke prevention in older adults with atrial fibrillation and comorbidity: current evidence and treatment challenges. Korean Circ J. 2018; 48:873–889.